A start-up with ambitions to disrupt the industry's long-standing drug pricing model could be a new threat to big pharma. EQRx has $200m in financing, a big-name leadership team and a mission to develop me-too drugs that cost a fraction of the cost of first-to-market brands.
EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs
With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.
More from Start-Ups & SMEs
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.
• By
The potential first-in-class antibody oligonucleotide conjugate could treat a form of the muscle wasting disease, and could be the first of Avidity’s trio of rare disease drugs to gain approval.
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.